Targeted liposome co-loaded with irinotecan hydrochloride and capecitabine, and preparation method and application thereof

Through peanut lectin-modified co-loaded irinotecan hydrochloride and capecitabine liposomes, the problem of targeting high expression of MUC1 in the prior art was solved, and effective targeted treatment for colorectal cancer was achieved. It significantly inhibits tumor cell proliferation and improves the therapeutic effect.

CN115054700BActive Publication Date: 2024-11-19WEIFANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210467089.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-29
Publication Date
2024-11-19
Estimated Expiration
2042-04-29

AI Technical Summary

Technical Problem

The existing co-loaded irinotecan hydrochloride and capecitabine PNA modified liposomes targeting highly expressed MUC1 colorectal cancer have not been reported, and it is difficult to effectively improve the anti-tumor effect of combined treatment.

Method used

By modifying peanut lectin (PNA), co-loading liposomes of irinotecan hydrochloride and capecitabine, targeted liposomes were prepared by thin-film dispersion method and ammonium sulfate gradient method to achieve the target of highly expressed MUC1 colorectal cancer cells Towards treatment.

Benefits of technology

It significantly inhibits the proliferation of colorectal cancer tissue cells, improves anti-tumor efficacy, provides higher clinical application value, and reduces the toxic side effects of chemotherapy drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115054700B_ABST
    Figure CN115054700B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and specifically relates to a targeted liposome co-loaded with irinotecan hydrochloride and capecitabine, and a preparation method and application thereof. The target is MUC1, because colorectal cancer expresses MUC1 significantly more than normal colorectal tissue, so PNA-modified liposomes that can specifically bind to MUC1 are used as modified liposomes targeted to colorectal cancer. The present invention proves that PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine have obvious active targeted drug delivery to colorectal cancer cells that highly express MUC1. In vivo experimental results show that compared with simple combined drug administration / unmodified dual-loaded / single-loaded liposomes, PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine have a significant effect of targeted inhibition of colorectal cancer proliferation, and have good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a targeted liposome co-loaded with irinotecan hydrochloride and capecitabine, and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] The topoisomerase I inhibitor irinotecan hydrochloride is widely used in the treatment of colorectal cancer and pancreatic cancer. It mainly relies on its active metabolite SN-38 to exert its anti-tumor effect. Considering tumor resistance, clinical treatment often uses combination therapy to treat cancer, such as irinotecan hydrochloride combined with 5-FU and its derivatives. Capecitabine is a prodrug of 5-FU. Studies have shown that the therapeutic effect of capecitabine combined with irinotecan on colorectal cancer patients is comparable to that of other synergistic regimens, but with the same efficacy, this regimen is well tolerated, has fewer toxic side effects, and is safer.

[0004] Anti-tumor drugs can cause toxic side effects such as neutropenia and diarrhea. In order to overcome the toxic side effects of chemotherapy drugs, studies have found that the use of liposomes to encapsulate irinotecan hydrochloride can reduce drug toxicity, improve drug stability, prolong drug half-life, and improve anti-tumor efficacy. In 2015, the FDA officially approved irinotecan hydrochloride-loaded liposomes for the treatment of pancreatic cancer. Irinotecan liposomes are unmodified and mainly fight tumors through passive targeting. The most common side effects of irinotecan liposome injection in patients are diarrhea, fatigue, vomiting, nausea, decreased appetite, oral inflammation, and fever.

[0005] Human mucin (MUC1) is a type of TACA and is a highly glycosylated mucin. Studies have shown that in malignant tumors such as breast cancer, liver cancer, and colorectal cancer, due to changes in the expression of glycosyltransferases, MUC1 has Thomsen-Friedenreich (TF) modification, which can reduce the adhesion between tumor cells. Increased expression levels of MUC1 promote tumor cell proliferation and metastasis, and are positively correlated with the degree of tumor malignancy and are related to the patient's poor prognosis.

[0006] Liposomes are a molecular ordered assembly of phospholipids spontaneously formed in water by hydrophobic association. They can encapsulate drugs in lipid bilayers to form microvesicles. Some people also call liposomes lipid globules or liquid crystal microcapsules. They have been used as a mature low-toxic and high-efficiency preparation for clinical treatment. However, the inventors found that there is no report on PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine targeting colorectal cancer with high MUC1 expression. Summary of the invention

[0007] In view of the above-mentioned deficiencies in the prior art, the present invention provides a targeted liposome co-loaded with irinotecan hydrochloride and capecitabine, and a preparation method and application thereof. The present invention further improves the anti-tumor effect of the combined treatment by modifying the co-loaded irinotecan hydrochloride and capecitabine liposomes with peanut agglutinin (PNA), laying a foundation for the development and research of a novel colorectal cancer treatment preparation with high expression of MUC1.

[0008] In order to achieve the above technical objectives, the technical solution of the present invention is as follows:

[0009] The first aspect of the present invention provides the use of irinotecan hydrochloride combined with capecitabine in the preparation of an anti-colorectal cancer drug.

[0010] The anti-colorectal cancer drug dosage form can be liposome.

[0011] The second aspect of the present invention provides a liposome, wherein the liposome comprises a pharmaceutically active ingredient and a lipid membrane material, wherein the pharmaceutically active ingredients are irinotecan hydrochloride and capecitabine; the lipid membrane material comprises phospholipids, cholesterol and DSPE-PEG2000-PNA; wherein the DSPE-PEG2000-PNA is DSPE-PEG2000 modified with peanut agglutinin.

[0012] The third aspect of the present invention provides a method for preparing the above liposome, which comprises preparing the above liposome by a thin film dispersion method and an ammonium sulfate gradient method.

[0013] The fourth aspect of the present invention provides the use of the above liposome in the preparation of anti-colorectal cancer drugs.

[0014] A fifth aspect of the present invention provides an anti-colorectal cancer drug, wherein the anti-colorectal cancer drug comprises the above-mentioned liposome.

[0015] Beneficial technical effects of one or more of the above technical solutions:

[0016] The above technical scheme found through in vivo and in vitro studies that PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine have excellent anti-tumor effects on colorectal cancer, and can significantly inhibit the proliferation of colorectal cancer tissue cells compared with the control group; it should also be noted that the above liposome product can be used for targeted treatment but is not limited to the MUC1-highly expressed colorectal cancer in the implementation scheme. All colorectal cancer cells that highly express MUC1 can be treated by the above liposome product. The above technical scheme provides more clinical application value for the irinotecan hydrochloride and capecitabine drug delivery system. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solution of the embodiment of the present invention, the drawings required for use in the description of the embodiment will be briefly introduced below. Obviously, the drawings in the following description are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0018] Figure 1 : Analysis of CI values ​​of four colorectal cancer cell lines at different IRI / CAP ratios in the examples of the present invention.

[0019] Figure 2 : This is the process optimization for preparing PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine in the examples of the present invention.

[0020] Figure 3 : Particle size, Zeta potential, EE and DL (`x±s, n=3) of different types of liposomes used in the examples of the present invention.

[0021] Figure 4 :Stability analysis of PNA modified liposomes co-loaded with irinotecan hydrochloride and capecitabine in the present invention. Notes: (A) Particle size changes of different types of liposomes in saline; (B) Particle size changes of different types of liposomes in 3% BSA; (C) Potential changes of different types of liposomes in saline; (D) Potential changes of different types of liposomes in 3% BSA.

[0022] Figure 5 : In vitro drug release analysis using co-drug-loaded liposomes in the examples of the present invention (A) In vitro drug release analysis of IRI in co-drug-loaded liposomes; (B) In vitro drug release analysis of CAP in co-drug-loaded liposomes.

[0023] Figure 6 :In vitro targeting analysis of PNA-modified liposomes in the examples of the present invention. (A) Fluorescence distribution of Caco-2 and HCT116 cells; (BC) Fluorescence intensity quantitative histogram of Caco-2 and HCT116 cells; (D) Fluorescence distribution of HT29 and SW620 cells; (EF) Fluorescence intensity quantitative histogram of HT29 and SW620 cells. ***P<0.001.

[0024] Figure 7 : The effect of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine on apoptosis of different colorectal cancer cells in the examples of the present invention. **P<0.01, ***P<0.001.

[0025] Figure 8:In vivo targeting analysis of PNA-modified liposomes in the present invention (A) Distribution of Cy7 in tumor-bearing nude mice after tail vein injection; (B) Quantitative histogram of fluorescence intensity of tumor tissue at each time point; (C) Distribution of fluorescence in important organs and tumor tissues after tumor-bearing nude mice were sacrificed 48 hours later; (D) Quantitative histogram of fluorescence intensity of tumor tissues after sacrifice. *P<0.05, **P<0.01, ***P<0.001.

[0026] Fig. 9 :In vivo anti-tumor analysis of IRI / CAP co-loaded PNA modified liposomes in the present invention (A) Photos of tumor-bearing nude mice in each treatment group after 20 days of treatment; (B) Line graph of weight changes of tumor-bearing nude mice in each treatment group; (C) Line graph of tumor volume changes of tumor-bearing nude mice in each treatment group; (D) Photos of tumor tissues in each treatment group; (E) Histogram of tumor tissue weight in each treatment group. **P<0.01, ***P<0.001.

[0027] Fig.10 : This is the biosafety analysis of liposomes modified with PNA in the examples of the present invention. DETAILED DESCRIPTION

[0028] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0029] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components and / or combinations thereof. It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the embodiments of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention.

[0030] As mentioned above, there are no reports on PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine targeting colorectal cancer with high MUC1 expression.

[0031] Peanut agglutinin (PNA) is a homotetrameric lectin extracted from peanuts, which can bind to a variety of disaccharides containing β-D-galactosyl-(1-3)-N-acetyl-D-galactosamine [Gal-β(1-3)GalNAc]. Previous studies have found that the core structure of the TF antigen in tumor-associated carbohydrate antigens (TACAs) including (MUC1, GD2, etc.) is Gal-β(1-3)GalNAc. Therefore, PNA-modified liposomes can be used to actively target colorectal cancer cells that highly express MUC1, concentrate drug delivery to tumor cells, and improve efficacy.

[0032] The modified liposomes can achieve active targeted transport while achieving passive targeting, which can reduce the use of chemotherapy drugs and reduce their toxic side effects while achieving the same therapeutic effect.

[0033] In view of this, in a specific embodiment of the present invention, the use of irinotecan hydrochloride combined with capecitabine in the preparation of an anti-colorectal cancer drug is provided. The present invention verifies through experiments that irinotecan hydrochloride and capecitabine have a strong synergistic anti-tumor effect on four colorectal cancer cells Caco-2, HCT116, HT29 and SW620, and the dosage ratio (w / w) of the two is 1-8:8-1; such as 8:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:8; preferably 3:1.

[0034] The anti-colorectal cancer drug dosage form can be liposome.

[0035] Therefore, in another specific embodiment of the present invention, a liposome is provided, wherein the liposome comprises a pharmaceutically active ingredient and a lipid membrane material, wherein the pharmaceutically active ingredients are irinotecan hydrochloride and capecitabine; the lipid membrane material comprises phospholipids, cholesterol and DSPE-PEG2000-PNA; wherein the DSPE-PEG2000-PNA is DSPE-PEG2000 modified with peanut agglutinin.

[0036] In another specific embodiment of the present invention, the feed ratio (w / w) of irinotecan hydrochloride to capecitabine is 2-5:1, such as 2:1, 3:1, 4:1 and 5:1; preferably 4:1;

[0037] The feed ratio (w / w) of the phospholipid, cholesterol and DSPE-PEG2000-PNA is 3-4:1:0.3-0.4, preferably 4:1:0.4;

[0038] The mass ratio of the phospholipid to capecitabine is 1:0.5-2, preferably 1:1.

[0039] In another specific embodiment of the present invention, a method for preparing the above liposome is provided, the method comprising preparing the above liposome by a thin film dispersion method and an ammonium sulfate gradient method;

[0040] Specifically, the preparation method comprises:

[0041] S1, preparation of DSPE-PEG2000-PNA;

[0042] S2. After mixing phospholipids, cholesterol and capecitabine, add DSPE-PEG2000-PNA and dissolve it in an organic solvent, remove the organic solvent and use a thin film dispersion method to form a lipid film, add ammonium sulfate solution to hydrate the obtained lipid film, filter and dialyze after low-temperature ultrasound; then add irinotecan hydrochloride solution thereto, incubate together, and dialyze to obtain the product.

[0043] Among them, in step S1, the preparation method of DSPE-PEG2000-PNA specifically includes: taking peanut agglutinin and dissolving it in PBS, adding DSPE-PEG2000-NH2 under heating conditions in a water bath until it is completely dissolved, stirring at room temperature, and then dialyzing and purifying the reaction solution, collecting the solution and freeze-drying it to obtain it.

[0044] In another specific embodiment of the present invention, the mass ratio of the peanut agglutinin to DSPE-PEG2000-NH2 is 0.5-2:1, preferably 1:1; the stirring time at room temperature is controlled to be 5-10h, preferably 8h;

[0045] The molecular weight cutoff of the dialysis bag used for dialysis purification is controlled to be 8000-14000Da, and the dialysis purification time is 40-50h, preferably 48h.

[0046] In another specific implementation of the present invention, in step S2,

[0047] The concentration of the ammonium sulfate solution is controlled to be 60-80 mg / mL, and the specific hydration conditions include: temperature 55-65° C., rotation speed 30-50 rpm, and time 0.5-2 h; preferably, temperature 60° C., rotation speed 40 rpm, and time 1 h.

[0048] During the low-temperature ultrasound process, the ultrasound temperature is controlled to be 0°C, the ultrasound time is 5-15 min, preferably 10 min, and the ultrasound is performed for 1-2 s with an interval of 2-3 s.

[0049] The filtration after low temperature ultrasound can be specifically performed by using a liposome extruder to filter through 0.5 μm and 0.2 μm filter membranes, 10 times each;

[0050] The molecular weight cutoff of the dialysis bag used in the dialysis after filtration is controlled to be 8000-14000Da, and the dialysis purification time is 1-5h, preferably 3h.

[0051] The concentration of irinotecan hydrochloride solution is controlled to be 8-12 mg / mL, preferably 10 mg / mL;

[0052] The specific conditions for the co-incubation are: the speed of the rotary evaporator is controlled at 30-50 rpm, the temperature is 50-70°C, and the incubation time is 20-60 min. Preferably, the rotary evaporator speed is 40 rpm and the temperature is 60°C for co-incubation for 30 min.

[0053] After the co-incubation, dialysis is performed using a dialysis bag, the molecular weight cutoff of the dialysis bag is controlled to be 8000-14000Da, and the dialysis purification time is 5-10 hours, preferably 8 hours.

[0054] In another specific embodiment of the present invention, there is provided use of the above liposome in the preparation of an anti-tumor drug, wherein the tumor is colorectal cancer.

[0055] In another specific embodiment of the present invention, an anti-colorectal cancer drug is provided, wherein the anti-colorectal cancer drug comprises the above-mentioned liposome.

[0056] The anti-colorectal cancer drug can also be added with other suitable excipients and additives and prepared into different dosage forms using techniques known in the art, such as injection, lyophilized powder for injection, liposome suspension, tablet, gel, implant, etc., for administration by intravenous injection, local injection, implantation, inhalation, etc.

[0057] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0058] Example

[0059] (1) Preparation of blank liposomes

[0060] Preparation of DSPE-PEG2000-PNA: Take 0.05g peanut agglutinin and dissolve it in 2mL PBS (pH7.4), add 0.05g DSPE-PEG2000-NH2 under heating conditions in a water bath until it is completely dissolved, stir at room temperature for 8h, then transfer the reaction solution to a dialysis bag (8000-14000Da) and dialyze and purify in 2L pure water for 48h, collect the solution and freeze-dry it to obtain DSPE-PEG2000-PNA.

[0061] Preparation of unmodified liposomes and PNA modified liposomes: Blank liposomes (Lip) and blank PNA modified liposomes (PNA-Lip) were prepared by thin film dispersion method. 20 mg of phospholipids and 5 mg of cholesterol (phospholipid: cholesterol = 4: 1) were mixed, 2 mg of DSPE-PEG2000-PNA was added or not added and dissolved in 2 mL of chloroform, transferred to a 50 mL eggplant-shaped bottle by water bath ultrasonic dissolution, and then installed on a rotary evaporator connected to a vacuum pump, placed in a 35°C water bath, and the vacuum pump was adjusted to make the negative pressure in the eggplant-shaped bottle between 0.045 MPa and 0.05 MPa, and the speed of the rotary evaporator was 20 rpm. After the last drop of chloroform disappeared, the vacuum pump was adjusted to make the negative pressure in the eggplant-shaped bottle reach the maximum. After maintaining the maximum negative pressure for 5 minutes, the organic solvent chloroform was completely removed and a uniform lipid film was formed on the inner wall of the eggplant-shaped bottle. After hydration with 70 mg / mL ammonium sulfate for 1 hour, the corresponding Lip and PNA-Lip were obtained.

[0062] (2) Preparation of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0063] Preparation of unmodified liposomes (IRI / CAP-Lip) / modified liposomes (IRI / CAP-PNA-Lip) co-loaded with irinotecan hydrochloride and capecitabine: Unmodified liposomes (IRI / CAP-Lip) co-loaded with irinotecan hydrochloride and capecitabine and unmodified liposomes PNA modified liposomes (IRI / CAP-PNA-Lip) co-loaded with irinotecan hydrochloride and capecitabine were prepared by the ammonium sulfate gradient method. 20 mg of phospholipid, 5 mg of cholesterol (phospholipid: cholesterol = 4:1) and 20 mg of capecitabine (CAP) (phospholipid: capecitabine = 1:1) were mixed, and 2 mg of DSPE-PEG2000-PNA was added or not, dissolved in 2 mL of chloroform, and transferred to a 50 mL eggplant flask under water bath ultrasonic dissolution. The chloroform was removed by rotary evaporator to form a lipid film. The operation was the same as that of blank liposome preparation. The obtained lipid film was added with 4 mL of ammonium sulfate solution (70 mg / mL) for hydration, and the hydration conditions were as follows: temperature 60°C, rotation speed 40 rpm, and time 1 hour. The film was ultrasonicated with an ice-water bath probe for 10 minutes (ultrasonic power 20%, ultrasonic time 10 minutes, ultrasonication 2 seconds interval 3 seconds), and after the ultrasonication, the film was passed through 0.5 μm and 0.2 μm filter membranes using a liposome extruder, 10 times each, and then transferred to a dialysis bag (8000-14000 Da) and dialyzed in 1 L of pure water for 3 hours to obtain liposomes modified with and without capecitabine (CAP) and ammonium sulfate PNA, respectively.

[0064] The co-loaded capecitabine (CAP) and ammonium sulfate PNA modified liposomes were transferred back to the eggplant-shaped bottle, 500ul irinotecan hydrochloride solution (10mg / mL, drug-lipid ratio = 1:4) was added, and the rotary evaporator speed was 40rpm and the temperature was 60°C for incubation for 30min. Irinotecan hydrochloride entered the liposome aqueous phase through active drug loading, and then moved to a dialysis bag (8000-14000Da) and dialyzed in 1L pure water for 8h to remove unencapsulated irinotecan hydrochloride. The water was changed every 2h. After the dialysis was completed, the corresponding IRI / CAP-Lip and IRI / CAP-PNA-Lip were obtained.

[0065] (3) Analysis of the optimal combination ratio of irinotecan hydrochloride and capecitabine.

[0066] The combination index (CI) method was used to analyze the optimal ratio of combined drug use. The concentrations of the main drug IRI were determined to be 1, 3, 9, 27, and 81 μg / mL, respectively. The concentration of CAP was determined according to IRI:CAP = 8:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, and 1:8, and a total of 45 IRI and CAP mixtures of different concentrations and ratios were obtained. Four colorectal cancer cell lines, Caco-2, HCT116, HT29, and SW620, which were in the logarithmic growth phase, were inoculated into 96-well plates (1×10 4 After culturing for 24 hours, 45 concentration gradient mixtures were added to treat the four cell lines for 72 hours, and the CI values ​​were analyzed to determine the optimal combination ratio.

[0067] The results are as follows Figure 1 As shown: The optimal combination ratio of irinotecan hydrochloride and capecitabine is 3:1.

[0068] (4) Optimization of the preparation process of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0069] By optimizing the process, the drug loading of irinotecan hydrochloride and capecitabine was adjusted to achieve the best synergistic ratio, and the PNA modified liposomes co-loaded with irinotecan hydrochloride and capecitabine achieved the best therapeutic effect. Phospholipid: cholesterol = 3:1, 4:1, and the feed ratio was adjusted to irinotecan hydrochloride: capecitabine = 2:1, 3:1, 4:1, and 5:1, and the drug loading ratio of irinotecan hydrochloride and capecitabine was tested respectively.

[0070] The optimization results are as follows Figure 2 As shown: when phospholipid: cholesterol = 4:1, irinotecan hydrochloride: capecitabine = 4:1, the drug loading ratio of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine meets the optimal combination ratio of the two drugs.

[0071] (5) Characterization and analysis of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0072] The particle size and potential distribution of blank liposomes and PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine were determined by Malvern particle size analyzer, and each measurement was repeated three times.

[0073] Calculation of encapsulation efficiency and drug loading of PNA modified liposomes co-loaded with irinotecan hydrochloride and capecitabine: The encapsulation efficiency and drug loading of PNA modified liposomes co-loaded with irinotecan hydrochloride and capecitabine were determined by high performance liquid chromatography. 300 μL of liposomes were diluted to 3 mL, and 2% Trinton X-100 was added to break the membrane for 20 minutes. The absorption peak areas of the samples at 254 nm and 307 nm were detected by high performance liquid chromatography, and the encapsulation efficiency was calculated by introducing the irinotecan hydrochloride standard curve and the capecitabine standard curve respectively.

[0074] Stability analysis of co-drug-loaded modified liposomes: The drug-loaded liposomes were dissolved in physiological saline and 3% BSA respectively and stored at 4°C for half a month. The particle size and potential were measured every other day. Each measurement was repeated three times to perform stability analysis on the co-drug-loaded modified liposomes.

[0075] The results are as follows Figure 3-4 As shown: the encapsulation efficiency (EE) of IRI / CAP-PNA-Lip for IRI and CAP were 89.45±0.015% and 7.56±0.014%, and the drug loading (DL) were 17.98±0.003% and 6.18±0.013%, respectively. The results were in line with the optimal synergistic ratio of IRI:CAP=3:1 and had good stability.

[0076] (6) In vitro drug release analysis of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0077] Take 2mL of drug-loaded liposomes and free drugs and place them in a dialysis bag. Place the dialysis bag in a conical flask filled with 50mL PBS. Place the conical flask in a shaker at a constant temperature of 37°C and 100 revolutions per minute. Take out 3mL of PBS at 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h, and add 3mL of fresh PBS. Use high performance liquid chromatography to detect the absorption peak areas of the samples at 254nm and 307nm, respectively, and bring them into the standard curve of irinotecan hydrochloride and the standard curve of capecitabine for calculation.

[0078] The results are as follows Figure 5 As shown: IRI and CAP showed sustained drug release in IRI / CAP-Lip and IRI / CAP-PNA-Lip, and the maximum cumulative release amount was lower than that of free drug.

[0079] (7) In vitro study of the colorectal cancer cell targeting ability of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0080] Lipid-soluble fluorescent FITC and water-soluble fluorescent rhodamine B were used to replace capecitabine and irinotecan hydrochloride, respectively, to prepare co-loaded fluorescent PNA-modified liposomes. The preparation method was the same as that of co-loaded PNA-modified liposomes. Colorectal cancer cell lines HT29 and SW620 with high expression of MUC1 and colorectal cancer cell lines Caco-2 and HCT116 without MUC1 expression were selected and 2×10 5 Cells / well were plated in 6-well plates and cultured overnight with DMEM medium containing 10% FBS. Free fluorescent drugs, co-loaded fluorescent liposomes and co-loaded fluorescent PNA-modified liposomes were added. After incubation for 4 hours, the uptake of PNA-modified drug-loaded liposomes by cells was observed using a laser confocal microscope.

[0081] The results are as follows Figure 6 As shown: Co-loaded fluorescent PNA modified liposomes can significantly target MUC1-positive colorectal cancer cell lines to co-deliver drugs and enhance cellular drug uptake.

[0082] (8) In vitro study on the anti-colorectal cancer effect of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0083] The colorectal cancer cell lines HT29 and SW620 with high expression of MUC1 and the colorectal cancer cell lines Caco-2 and HCT116 without MUC1 expression were selected and the cells were cultured at 2×10 5 Cells were plated in 6-well plates and cultured overnight in DMEM medium containing 10% FBS. After adding liposomes of different formulations and incubating for 24 hours, flow cytometry was used to detect the induction of cell apoptosis by PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine.

[0084] The results are as follows Figure 7 Shown: PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine significantly induced apoptosis of MUC1-positive colorectal cancer cells.

[0085] (9) In vivo study on the colorectal cancer targeting effect of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0086] A subcutaneous tumor-bearing nude mouse model was constructed using the colorectal cancer cell line SW620 with high expression of MUC1. Lipid Cy7 was selected to replace the drug and loaded into the hydrophilic core of the liposome to prepare fluorescently labeled PNA-modified liposomes. After tail vein injection, a small animal in vivo imaging device was used to take photos to observe the tissue distribution of fluorescence in the body and analyze the in vivo targeting ability of PNA-modified liposomes.

[0087] The results are as follows Figure 8Shown: PNA-modified liposomes can significantly target colorectal cancer tissues with high expression of MUC1.

[0088] (10) In vivo study on the anti-colorectal cancer effect of PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine

[0089] The nude mice were divided into 4 groups (6 mice in each group) according to the tumor volume. Normal saline (NS), IRI / CAP, IRI / CAP-Lip, IRI / CAP-PNA-Lip (C IRI =20 mg / kg). The tumor tissue volume and body weight were measured every other day. After 20 days of treatment, the nude mice were killed, the tumor tissue was taken, photographed and weighed, and the tumor inhibition rate of each treatment group was calculated.

[0090] The results are as follows Fig. 9 As shown: PNA-modified liposomes co-loaded with irinotecan hydrochloride and capecitabine can significantly inhibit the proliferation of colorectal cancer with high expression of MUC1.

[0091] (11) Biosafety Analysis of PNA-modified Liposomes Co-loaded with Irinotecan Hydrochloride and Capecitabine

[0092] The hearts, livers, spleens, lungs, and kidneys of tumor-bearing nude mice were taken for histological analysis to analyze the biosafety of IRI / CAP-PNA-Lip.

[0093] The results are as follows Fig.10 As shown: No obvious histopathological abnormalities were found in the important organs of each treatment group. PNA modified liposomes have good biological safety.

[0094] It should be noted that the above examples are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention is described in detail with reference to the given examples, those skilled in the art may modify or replace the technical solution of the present invention as needed without departing from the spirit and scope of the technical solution of the present invention.

Claims

1. A use of liposomes in the preparation of anti-colorectal cancer drugs, characterized in that: The liposome comprises a pharmaceutically active ingredient and a lipid membrane material, wherein the pharmaceutically active ingredient is irinotecan hydrochloride and capecitabine; the lipid membrane material comprises phospholipids, cholesterol and DSPE-PEG2000-PNA; wherein the DSPE-PEG2000-PNA is DSPE-PEG2000 modified with peanut agglutinin; The feeding ratio of irinotecan hydrochloride to capecitabine ( w / w ) is 4:1; The feed ratio of phospholipid, cholesterol and DSPE-PEG2000-PNA ( w / w ) is 4:1:0.4; The mass ratio of the phospholipid to capecitabine is 1:0.5-2; The preparation method of the liposome includes preparing by thin film dispersion method and ammonium sulfate gradient method; Characterized in that the preparation method of the liposome comprises: S1, preparation of DSPE-PEG2000-PNA; S2, after mixing phospholipids, cholesterol and capecitabine, add DSPE-PEG2000-PNA and dissolve it in an organic solvent, remove the organic solvent and form a lipid film by a thin film dispersion method, add ammonium sulfate solution to the obtained lipid film for hydration, filter and dialyze after low-temperature ultrasound; then add irinotecan hydrochloride solution thereto, incubate together, and dialyze to obtain; In the step S1, The preparation method of DSPE-PEG2000-PNA specifically includes: dissolving peanut agglutinin in PBS, adding DSPE-PEG2000-NH2 under water bath heating conditions until it is completely dissolved, stirring at room temperature, and then dialysis purification of the reaction solution, collecting the solution and freeze-drying it to obtain the product; In the step S2, The concentration of the ammonium sulfate solution is controlled to be 60-80 mg / mL, and the specific hydration conditions include: temperature 55-65°C, rotation speed 30-50 rpm, and time 0.5-2 h; During the low-temperature ultrasound process, the ultrasound temperature was controlled to be 0°C, the ultrasound time was 5-15min, and the ultrasound was 1-2s with an interval of 2-3s; The molecular weight cutoff of the dialysis bag used in the dialysis after filtration is controlled to be 8000-14000Da, and the dialysis purification time is 1-5h; The concentration of irinotecan hydrochloride solution is controlled at 8-12 mg / mL; The specific conditions for the co-incubation are: the speed of the rotary evaporator is controlled at 30-50 rpm, the temperature is 50-70°C, and the incubation time is 20-60 min; After the co-incubation, dialysis is performed using a dialysis bag, the molecular weight cutoff of the dialysis bag is controlled to be 8000-14000Da, and the dialysis purification time is 5-10h.

2. The use according to claim 1, characterized in that The mass ratio of the phospholipid to capecitabine is 1:

1.

3. The use according to claim 1, characterized in that The mass ratio of the peanut lectin to DSPE-PEG2000-NH2 is 0.5-2:1, and the stirring time at room temperature is controlled to be 5-10 hours.

4. The use according to claim 3, characterized in that The mass ratio of the peanut lectin to DSPE-PEG2000-NH2 is 1:1, and the stirring time at room temperature is controlled to be 8 hours.

5. The use according to claim 1, characterized in that In the preparation method of DSPE-PEG2000-PNA, the molecular weight cutoff of the dialysis bag used for dialysis purification is controlled to be 8000-14000Da, and the dialysis purification time is 40-50h.

6. The use according to claim 5, characterized in that The dialysis purification time is 48h.

7. The use according to claim 1, characterized in that The specific hydration conditions include: temperature 60°C, rotation speed 40 rpm, and time 1 h.

8. The use according to claim 1, characterized in that During the low-temperature ultrasound process, the ultrasound time was controlled at 10 min.

9. The use according to claim 1, characterized in that The molecular weight cutoff of the dialysis bag used in the dialysis after filtration was controlled to be 8000-14000Da, and the dialysis purification time was 3h.

10. The use according to claim 1, characterized in that The concentration of irinotecan hydrochloride solution was controlled to be 10 mg / mL.

11. The use according to claim 1, characterized in that The specific conditions for the co-incubation are: the rotary evaporator speed is 40 rpm, and the temperature is 60° C. for 30 minutes.

12. The use according to claim 1, characterized in that After the co-incubation, dialysis was performed using a dialysis bag, the molecular weight cutoff of the dialysis bag was controlled to be 8000-14000Da, and the dialysis purification time was 8h.